Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJ37IX)

• Drug Name: L-775606 Drug Info
• Synonyms: L-775606; L-775,606; CHEMBL292779; 188400-51-3; 1-(3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl)-4-(2-(3-fluorophenyl)ethyl)piperazine; 3-[3-[4-[2-(3-fluorophenyl)ethyl]piperazin-1-yl]propyl]-5-(1,2,4-triazol-4-yl)-1H-indole; ZUTQCPBDRJBADG-UHFFFAOYSA-N; 1-[3-(5-(1,2,4-Triazol-4-yl)-1H-indol-3-yl)propyl]-4-[2-(3-fluorophenyl)ethyl]piperazine; 1-(3-[5-{1,2,4-triazol-4-yl}-1h-indol-3-yl]propyl)-4-(2-{3-fluorophenyl}ethyl)piperazine; AC1O52LD; GTPL114; L 775606; SCHEMBL7477108; BDBM50060437; L016148; 1H-Indole, 3-(3-(4-(2-
• Cross-matching ID:
  PubChem CID: 6426760
  CAS Number: CAS 188400-51-3
  TTD Drug ID: DMJ37IX

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 1B receptor (HTR1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[3]
Eletriptan	DMW649X	Migraine	8A80	Approved	[4]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[4]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[4]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[4]
Naratriptan	DMO50U2	Headache	8A80-8A84	Approved	[5]
Prolixin decanoate	DMMJ1IS	Schizophrenia	6A20	Approved	[4]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[6]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[7]
[N-methyl-3H(3)]AZ-10419369	DMSCV02	Mood disorder	6A60-6E23	Phase 1	[8]

Drug(s) Targeting 5-HT 1D receptor (HTR1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[9]
Eletriptan	DMW649X	Migraine	8A80	Approved	[4]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[4]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[4]
Sumatriptan	DMVYXR8	Cluster headache	8A81.0	Approved	[10]
Rizatriptan	DMDJMA3	Migraine	8A80	Approved	[11]
Almogran	DM7I64Z	Migraine	8A80	Approved	[12]
Neu-P11	DMIQDFW	Alzheimer disease	8A20	Phase 2	[13]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[14]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1B receptor (HTR1B)	TTK8CXU	5HT1B_HUMAN	Inhibitor	[1]
5-HT 1D receptor (HTR1D)	TT6MSOK	5HT1D_HUMAN	Inhibitor	[2]

References

• [1] Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents. J Med Chem. 1997 Oct 24;40(22):3501-3.
• [2] Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-pip... J Med Chem. 2008 Jun 26;51(12):3609-16.
• [3] Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
• [6] Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
• [7] Company report (NeurAxon)
• [8] 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
• [9] Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
• [10] Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
• [11] An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
• [12] Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
• [13] Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)